Hyzaar: profile and news

DuPont plans for lost income Feb 16, 2006
...bio-based Sorona fiber and products made for the electronics industry to replace revenue that will be lost once royalties from its Cozaar and Hyzaar high blood ... - The News Journal,

DuPont expects profit drop as drug goes off patent in 2010 Feb 15, 2006
DuPont Co. will see a rapid drop in profits from hypertension drug Cozaar/Hyzaar starting in 2010, Chief Executive Officer Charles O. Holliday Jr. ... - The News Journal,

Merck profits edge ahead in fourth quarter Feb 1, 2006
Merck's blood pressure treatment range, headed by Cozaar (losartan) and Hyzaar (losartan and hydrochlorothiazide), advanced 2% to $782 million in the fourth ... - Pharma Times (subscription),

Merck Marking Time Jan 31, 2006
There was good growth from Singulair, but most of the other large drugs, including Cozaar/Hyzaar, Fosamax, and Zocor, saw sales either barely up (2% growth for ... - Motley Fool

Merck Earnings Top Estimates Jan 31, 2006
Among major drugs, fourth-quarter sales of asthma treatment Singulair rose 12% to $819 million; sales of blood-pressure drugs Cozaar and Hyzaar rose 2% to $782 ... - TheStreet.com

DuPont Shares Look 'Deceptively Cheap' Jan 12, 2006
Rita, research analyst Kevin McCarthy said he remains cautious on DuPont due to the company's patent expirations for hypertension drugs Cozaar and Hyzaar and a ... - Forbes

DuPont "neutral," target price reduced Jan 13, 2006
DuPont’s Cozaar/Hyzaar pharma patents are scheduled to expire in 2010, the analyst says. The EPS estimate for 2006 has been reduced from $2.75 to $2.30. - New Ratings

Merck results better than expected Jan 31, 2006
Sales of asthma and allergy treatment Singulair rose 12 percent to $819 million, while sales of hypertension treatment Cozaar/Hyzaar rose 2 percent to $782 ... - Reuters

Merck profit slightly higher, beats forecasts Jan 31, 2006
Combined sales of hypertension treatments Cozaar and Hyzaar rose just 2 percent to $782 million, and sale of osteoporosis treatment Fosamax fell 5 percent to ... - Reuters

DuPont earnings dip 45% Jan 25, 2006
DuPont received royalties of $203 million from sales of Cozaar and Hyzaar, a pair of drugs for treating high blood pressure it licenses to Merck & Co. ... - The News Journal,

Merck profit beats estimates, sales rise to $5.77 bln Jan 31, 2006
...million from last year. Combined sales of its Cozaar/Hyzaar blood pressure drug franchise rose 2% to $782 million. The company's top ... - Investor's Business Daily (subscription)

Merck Announces Initial Steps In Global Restructuring Program Nov 28, 2005
2005 SALES ----- ZOCOR (Cholesterol modifying) $4.2 to $4.5 billion FOSAMAX (Osteoporosis) $3.1 to $3.4 billion COZAAR/HYZAAR (Hypertension) $2.9 ... - Business Wire (press release),

Merck shedding 7,000 jobs Nov 29, 2005
DuPont, which developed a pair of anti-hypertension drugs with Merck, licenses the drugs, Cozaar and Hyzaar, to Merck and receives royalties. ... - The News Journal,

Merck to Cut 7,000 Jobs, Close 5 Manufacturing Plants (Update2) Nov 28, 2005
Sales of the Cozaar/Hyzaar high- blood pressure treatment is expected to be flat at $2.9 billion to $3.2 billion, while revenue from Singulair for asthma may ... - Bloomberg

Merck to Cut 7,000 Jobs, Close 5 Manufacturing Plants (Update3) Nov 28, 2005
Sales of the Cozaar/Hyzaar high- blood pressure treatment will be unchanged $2.9 billion to $3.2 billion next year, while revenue from Singulair for asthma may ... - Bloomberg

Pfizer's Troubles Pull Down Drugmakers Nov 21, 2005
Singulair, a once-daily asthma drug that had an 11% sales gain in the quarter to $692 million, while the antihypertensive medicines Cozaar and Hyzaar enjoyed 6 ... - Chemical & Engineering News

FDA Approvals: Hyzaar, Levemir, NovoLog/Novolin R Oct 27, 2005
20, the FDA approved a new 100-mg/12.5-mg dose for losartan potassium plus hydrochlorothiazide (HCTZ) fixed-dose combination tablets (Hyzaar, made by Merck & Co ... - Medscape (subscription)

Titration-Extension Study Shows Losartan-Based Treatment ... Oct 24, 2005
...seen in family physician settings, the TITRATION-EXTENSION study demonstrated that the approach of using Cozaar(R) (losartan potassium), Hyzaar(R) (losartan ... - DG News

Merck Needs to Take Its Medicine Oct 24, 2005
Zocor was down, Fosamax was flat, and Cozaar/Hyzaar sales were up in the mid-single digits. But Singulair continued to grow at a double-digit clip. ... - MSNBC

Merck "neutral weight" Oct 25, 2005
The sales of the company's key products, Zocor, Fosamax, Cozaar/Hyzaar and Singulair, were lower than expected, the analyst says. ... - New Ratings

Merck Shows Some Upside Oct 24, 2005
Other big drugs sold well, including Merck's blood-pressure drugs Cozaar and Hyzaar, which saw revenue rise 6% from a year ago to $751 million. ... - TheStreet.com

Old Vioxx Charge Helps Merck Show Gain Oct 24, 2005
Osteoporosis treatment Fosamax saw sales of $777 million "comparable" with last year, while sales of blood pressure drugs Cozaar and Hyzaar increased 6% to ... - Smartmoney.com

Merck shares end day off less than 1% Aug 23, 2005
...two years at least through 2012." They include cholesterol drug Zocor in 2006, osteoporosis drug Fosamax in 2008, blood pressure medicine Cozaar/Hyzaar in 2010 ... - philly.com,

CHS Welcomes Two New Marketing Professionals Aug 22, 2005
...as associate director of marketing, hypertension/heart failure, where he led the development of marketing strategy to reposition the Cozaar and Hyzaar franchise ... - PharmaLive.com (press release),

Q2 2005 Merck & Co., Inc. Sales and Earnings Conference Call ... Jul 29, 2005
Excluding the net tax charge of $640m, MRK anticipates full-year 2005 EPS of $2.44-2.52. Q&A Focus: VYTORIN, R&D, and COZAAR/HYZAAR franchise. ... - Research and Markets (subscription)

Merck Announces Second-Quarter 2005 Earnings Per Share (EPS) of 33 ... Jul 21, 2005
Global sales of Merck's antihypertensive medicines, COZAAR and HYZAAR**, remained solid, reaching $785 million for the second quarter and representing growth ... - Business Wire (press release)

Merck Is No Quack Jul 21, 2005
Singulair was the only drug of substantial size to post double-digit growth (14%). Fosamax and Cozaar/Hyzaar both grew in the high single digits. ... - Motley Fool

Update 3: Merck Q2 Profit Dips on One-Time Tax Charge Jul 21, 2005
Revenues from the related blood pressure drugs Cozaar and Hyzaar also rose 8 percent, to $785 million, and asthma drug Singulair had sales jump 14 percent, to ... - Forbes

Update 3: Legal Problems, Taxes Drag Drug Makers Jul 21, 2005
...billion, but higher sales of asthma drug Singulair, osteoporosis medication Fosamax and the related blood pressure drugs Cozaar and Hyzaar helped compensate. ... - Forbes

Microsoft's Net Income Climbs 38% Jul 22, 2005
...and allergy drug, recorded sales of $730 million, up 14%, while Fosamax, an osteoporosis drug, had sales of $853 million, up 8%. Cozaar and Hyzaar, two blood ... - 123Jump (subscription)

Merck falls on Vioxx withdrawal Jul 21, 2005
Merck's blood pressure drugs, Cozaar and Hyzaar had combined sales of $785 million, up 8% over last year, while its Fosamax osteoporosis drug franchise ... - Investor's Business Daily (subscription)

A Good Deal All Around Jul 21, 2005
Although Merck has had recent success in hypertension and cholesterol treatments — its Cozaar, Hyzaar and Zocor should combine for sales of more than $7 ... - Smartmoney.com (subscription)

Water Pills and Night Sweats Jul 19, 2005
Combination drugs include Aldoril, Atacand HCT, Avalide, Benicar HCT, Diovan HCT, Dyazide, Hyzaar, Lotensin HCT, Maxzide, Micardis HCT, Moduretic, Prinzide ... - Saturday Evening Post

Merck says Vioxx withdrawal hurt profit Apr 21, 2005
Its blood-pressure drugs, Cozaar and Hyzaar, posted a sales increase of 14 percent, to reach $719 million for the quarter, the company said. ... - Newark Star Ledger,

FDA Approvals: Hyzaar, Panzem, Decapinol Apr 21, 2005
On April 5, the FDA approved a new indication for losartan potassium plus hydrochlorothiazide (HCTZ) tablets (Hyzaar, made by Merck & Co.), allowing its use to ... - Medscape (subscription)

Merck gets expanded FDA OK for Hyzaar Apr 14, 2005
...said Thursday that regulators expanded the approved uses for its Hyzaar hypertension drug, which is now indicated to reduce stroke risk in patients with high ... - BusinessWeek

Merck First-Quarter Earnings Fall Apr 21, 2005
Asthma drug Singulair and hypertension treatments Cozaar and Hyzaar continued to be profitable. Singulair rose 18 percent to $735 ... - ObviousNews.com

Merck Earns Fall After Vioxx Withdrawal Apr 21, 2005
First-quarter sales of asthma drug Singulair rose 18 percent to $735 million, while sales of hypertension medicines Cozaar and Hyzaar increased 14 percent to ... - MSN Money

Merck 1Q Profit Slips As Sales Suffer Apr 21, 2005
Its hypertension drugs, Cozaar and Hyzaar, posted a sales increase of 14 percent to reach $719 million for the quarter, the company said. - ObviousNews.com

Merck Says FDA OKs New Use of Hypertension Drug Apr 14, 2005
...said on Thursday that US regulators approved a new use of its combination hypertension drug Hyzaar -- reducing the risk of stroke in patients with high blood ... - Reuters

Merck Comes Through on Guidance Apr 21, 2005
Asthma treatment Singulair did $735 million in revenue, up 18% from a year ago, while its blood pressure treatment's Cozaar and Hyzaar totaled $719 million, up ... - TheStreet.com

Merck Looks for Soft Landing Apr 21, 2005
Among the company's biggest products, Singulair revenue grew 18% to $735 million, and Cozaar/Hyzaar sales grew 14% to $719 million. ... - Motley Fool

Merck's profits fall on lost Vioxx sales Apr 21, 2005
Its blood-pressure drugs, Cozaar and Hyzaar, posted a sales increase of 14 percent to reach $719 million for the quarter, the company said. ... - BusinessWeek

Profit at Merck falls in first quarter Apr 21, 2005
Its hypertension drugs, Cozaar and Hyzaar, also posted a sales increase of 14 per cent to reach $US719 million for the quarter, the company said. ... - Sydney Morning Herald (subscription)

Merck under investigation over Vioxx Apr 21, 2005
When Vioxx is not included in last year's figures, the group's sales grew in the first quarter, helped by its blood pressure drugs Cozaar and Hyzaar as well as ... - Guardian

Merck Upbeat on Second Quarter Apr 21, 2005
...$735 million. Revenue from blood pressure medicines Cozaar and Hyzaar rose 14% to $719 million during the period. Costs, expenses ... - Smartmoney.com (subscription)

Drugs & Devices Report Apr 14, 2005
WHITEHOUSE STATION, New Jersey – The FDA approved an added use for Merck-made drug Hyzaar. The antihypertensive drug now also ... - Red Herring

Stroke cases on the rise in the country Apr 20, 2005
Meanwhile, the US Food and Drug Administration (FDA) has approved Hyzaar as the first fixed-dose combination hypertension medicine to help prevent strokes in ... - Khaleej Times,

When given concurrently the following drugs may interact with thiazide diuretics.

Alcohol, barbiturates, or narcotics: potentiation of orthostatic hypotension may occur.

Antidiabetic drugs: (oral agents and insulin) - dosage adjustment of the antidiabetic drug may be required.

Other antihypertensive drugs: additive effect or potentiation.

Cholestyramine and colestipol resins: Absorption of hydrochlorothiazide is impaired in the presence of anionic exchange resins. Single doses of either cholestyramine or colestipol resins bind the hydrochlorothiazide and reduce its absorption from the gastrointestinal tract by up to 85 and 43 percent, respectively.

Corticosteroids, ACTH: intensified electrolyte depletion, particularly hypokalemia.

Pressor amines (e.g., norepinephrine): possible decreased response to pressor amines but not sufficient to preclude their use.

Skeletal muscle relaxants, nondepolarizing (e.g., tubocurarine): possible increased responsiveness to the muscle relaxant.

Lithium: generally should not be given with diuretics. Diuretic agents reduce the renal clearance of lithium and add a high risk of lithium toxicity. Refer to the package insert for lithium preparations before use of such preparations with Hydrochlorothiazide.

Non-steroidal Anti-inflammatory Drugs: In some patients, the administration of a non-steroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium-sparing and thiazide diuretics. Therefore, when Hydrochlorothiazide and non-steroidal anti-inflammatory agents are used concomitantly, the patient should be observed closely to determine if the desired effect of the diuretic is obtained.